Detalles de la búsqueda
1.
IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
Int J Technol Assess Health Care
; 34(5): 458-463, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334508
2.
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.
Front Oncol
; 14: 1368606, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38571509
3.
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.
Front Oncol
; 13: 1170124, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333804
4.
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
J Med Econ
; 26(1): 411-421, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36897006
5.
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Int J Clin Pharm
; 45(3): 604-612, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37010731
6.
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China.
Patient Relat Outcome Meas
; 14: 253-267, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789883
7.
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.
Diabetes Ther
; 13(4): 651-677, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35290625
8.
Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
J Med Econ
; 25(1): 561-570, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403540
9.
Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.
Pharmacoecon Open
; 5(2): 143-155, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33638063
10.
Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review.
J Cancer Surviv
; 15(6): 961-975, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33624172
11.
Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.
Clinicoecon Outcomes Res
; 11: 605-614, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31632108
12.
Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Diabetes Technol Ther
; 21(3): 110-118, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785311
13.
Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
Diabetes Ther
; 10(2): 493-508, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706364
14.
Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
J Diabetes Sci Technol
; 13(5): 910-918, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30700165
15.
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
Diabetes Ther
; 8(2): 401-415, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28224463
Resultados
1 -
15
de 15
1
Próxima >
>>